Zalicus, Inc. (ZLCS) Finalizes Patient Enrollment in Phase IIb Trial of Synavive
Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company has a number of proprietary drug product candidates that are currently in clinical trials. The company today announced it has completed the enrollment of 292 patients in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of the Zalicus' Synavive drug. Synavive is a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits in patients with rheumatoid arthritis. The trial is a 12-week, five-arm, global, double-blind, placebo-controlled study designed to evaluate the company's…